PMID- 11878205
OWN - NLM
STAT- MEDLINE
DCOM- 20020327
LR  - 20220408
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 52
IP  - 2
DP  - 2002
TI  - Effects of antihistamines on leukotriene and cytokine release from dispersed 
      nasal polyp cells.
PG  - 97-102
AB  - In this study the effects of antihistamines on the release of eicosanoids and the 
      pro-inflammatory cytokine tumor necrosis factor alpha (TNF alpha) were compared. 
      Enzymatically dispersed cells from human nasal polyps served as an in vitro model 
      of chronic respiratory mucosal inflammation. Nasal polyp cells (2 x 10(5)/ml) 
      were sensitized with human IgE pre-incubated azelastine (CAS 58581-89-8), 
      terfenadine (CAS 50679-08-8), levocabastine (CAS 79516-68-0) or cetirizine (CAS 
      83881-51-0), and stimulated with anti-human immunoglobulin E (IgE). Thromboxane 
      B2 (TBX2) and leukotriene C4 (LTC4) were measured by radioimmunoassay (RIA), TNF 
      alpha by enzyme-linked immunosorbent assay (ELISA). Data represent mean values of 
      % inhibition estimated from the untreated positive control or mean IC50 (n = 5). 
      Azelastine and terfenadine inhibited TNF alpha release with IC50 values of 6.2 
      mumol/l and 4.3 mumol/l, respectively. Terfenadine reduced TXB2 release by 37 +/- 
      15%, and LTC4 release was decreased by azelastine and terfenadine very potently 
      by 86% and 100%, respectively. Azelastine shows anti-inflammatory properties in 
      therapeutically relevant concentrations as assessed by its ability to reduce TNF 
      alpha release as well as its ability to inhibit LTC4 production in allergically 
      stimulated human nasal polyp cells.
FAU - Kusters, Sabine
AU  - Kusters S
AD  - Pulmonary Pharmacology, Corporate Research ASTA Medica AG/Arzneimittelwerk 
      Dresden GmbH, Radebeul, Germany.
FAU - Schuligoi, Rufina
AU  - Schuligoi R
FAU - Huttenbrink, Karl-Bernd
AU  - Huttenbrink KB
FAU - Rudert, Jutta
AU  - Rudert J
FAU - Wachs, Angela
AU  - Wachs A
FAU - Szelenyi, Istvan
AU  - Szelenyi I
FAU - Peskar, Bernhard A
AU  - Peskar BA
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Cytokines)
RN  - 0 (Eicosanoids)
RN  - 0 (Histamine Antagonists)
RN  - 0 (Leukotrienes)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 2CU6TT9V48 (Leukotriene C4)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 54397-85-2 (Thromboxane B2)
SB  - IM
MH  - Cytokines/*metabolism
MH  - Eicosanoids/metabolism
MH  - Epithelial Cells/drug effects/metabolism
MH  - Histamine Antagonists/*pharmacology
MH  - Humans
MH  - Immunoglobulin E
MH  - Leukotriene C4/metabolism
MH  - Leukotrienes/*metabolism
MH  - Nasal Polyps/*metabolism/pathology
MH  - Thromboxane B2/metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2002/03/07 10:00
MHDA- 2002/03/28 10:01
CRDT- 2002/03/07 10:00
PHST- 2002/03/07 10:00 [pubmed]
PHST- 2002/03/28 10:01 [medline]
PHST- 2002/03/07 10:00 [entrez]
AID - 10.1055/s-0031-1299863 [doi]
PST - ppublish
SO  - Arzneimittelforschung. 2002;52(2):97-102. doi: 10.1055/s-0031-1299863.